After recognizing some patients with a rare autoimmune neuromuscular disease, known as Lambert-Eaton myasthenic syndrome (LEMS), were unable to access treatment for their disease, Florida drug maker Catalyst Pharmaceutical Partners stepped up and initiated the process to establish an expanded access program (EAP) for its experimental potassium channel inhibitor Firdapse (amifampridine phosphate).
Catalyst CEO Patrick McEnany told Scrip the company plans to make Firdapse, which currently is in Phase III development, available...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

